Posts Tagged ‘Insulin’

Outpatient intravenous insulin therapy (OIVIT) is to remain nationally noncovered. The Centers for Medicare & Medicaid Services (CMS) recently concluded that OIVIT does not improve health outcomes and is not reasonable and necessary for any indication. Read more »

Diabetes patients taking NovoLog® (HCPCS Level II code S5551 Insulin, most rapid onset (Lispro or Aspart); 5 units) can now use the insulin in their pump for up to six days. Diabetes care company Novo Nordisk announced Food and Drug Administration (FDA) approval of this labeling change July 21. The previous label allowed for NovoLog® to be stored in the pump reservoir for two days.

The updated label also states patients using NovoLog® in their pumps should change the infusion set and the infusion set insertion site at least every three days. The previous label stated that NovoLog® in the pump reservoir, infusion set and the infusion set insertion site be changed at least every 48 hours.

Let diabetic patients know Tyco Healthcare Group LP (Covidien) recalled one lot of ReliOn 31-gauge, 1cc insulin syringes due to possible mislabeling.

According to a U.S. Food and Drug Administration Nov. 5 news release, there was a mix up during the packaging process and some syringes labeled for use with U-40 insulin were mixed with syringes labeled for use with U-100 insulin. The syringes were then packaged individually and boxed as 100 units for use with U-100 insulin. Read more »